Business Context and Reporting Period
Company: Surrozen, Inc. (SRZN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Surrozen is a biotechnology company developing biologic drug candidates to selectively modulate the Wnt pathway for tissue repair, with a primary focus on ophthalmology. The company utilizes its proprietary SWAP (Surrozen Wnt signal Activating Protein) technology to create tissue-selective therapeutics. Key product candidates include SZN-413 (in collaboration with Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $10.7 million | $0 |
| Net Loss | $(63.6) million | $(43.0) million |
| Operating Expenses | $36.2 million | $45.8 million |
| Cash and Cash Equivalents (Year End) | $34.6 million | $36.0 million |
| Accumulated Deficit | $(285.3) million | $(221.7) million |
| Warrant Liabilities | $55.9 million | $0.1 million |
Note: The 2024 net loss includes a non-cash loss of $20.4 million on the issuance of common stock and warrants in a private placement and a $17.8 million non-cash change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Generation: The company generated $10.7 million in revenue in 2024, compared to zero in 2023. This was driven by a $10.0 million milestone payment from Boehringer Ingelheim (BI) for the advancement of SZN-413 and $0.7 million in research service revenue from a related party collaboration.
- Operating Expenses: Total operating expenses decreased by 21% to $36.2 million. Research and Development (R&D) expenses declined 22% to $21.1 million, primarily due to workforce reductions in 2023 and the discontinuation of the SZN-1326 program. Restructuring charges were $0 in 2024 compared to $2.8 million in 2023.
- Non-Operating Items: "Other (expense) income, net" swung from a $0.4 million gain in 2023 to a $19.3 million expense in 2024, largely due to the fair value adjustment of warrant liabilities.
- Liquidity: Cash used in operating activities improved significantly to $17.6 million in 2024 from $40.4 million in 2023.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Surrozen expects to continue incurring significant losses for the foreseeable future. As of December 31, 2024, the company held $34.6 million in cash. Management believes this, combined with approximately $76.4 million in gross proceeds from a private placement closed in March 2025, is sufficient to fund operations for at least the next 12 months. The company anticipates needing substantial additional capital to advance clinical trials and commercialize products.
Recent Developments (Subsequent Events):
- March 2025 Private Placement: Closed the first tranche of a two-tranche private placement, raising approximately $76.4 million. The second tranche is contingent on FDA clearance of an IND for SZN-8141 by October 31, 2026.
- Program Discontinuation: In March 2025, the company discontinued development of SZN-043 for severe alcohol-associated hepatitis due to insufficient early clinical benefit signals.
Key Risks:
- Regulatory Approval: No product candidates have received regulatory approval; success depends on clinical trial outcomes.
- Liquidity: The company has a history of losses and requires additional financing to continue operations.
- Collaboration Dependence: Significant revenue and development progress rely on the collaboration with Boehringer Ingelheim.
- Warrant Liability Volatility: Fluctuations in stock price and milestone probabilities significantly impact reported net loss due to warrant liability accounting.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.6 million year-end cash balance plus the $76.4 million March 2025 proceeds against the projected burn rate for clinical trials.
- Warrant Liability Impact: Assess the sensitivity of future earnings to changes in the fair value of the $55.9 million warrant liability.
- BI Collaboration Milestones: Monitor the progress of SZN-413 development by Boehringer Ingelheim to determine the likelihood of future milestone payments (up to $587 million potential).
- Second Tranche Conditions: Track the status of the IND application for SZN-8141, as the second tranche of the March 2025 financing ($98.6 million potential) is contingent on FDA clearance by late 2026.
- Program Pipeline: Confirm the strategic focus on ophthalmology candidates (SZN-8141, SZN-8143, SZN-113) following the discontinuation of SZN-043.